SlideShare a Scribd company logo
1 of 4
Download to read offline
1
Setco Automotive
Sensex: 25908 CMP:INR134 Target: INR 159
Auto Ancillaries
OE sales up 23.2%, replacement sales up 74.5%
OE sales grew 23.2% YoY to INR 301 mn whereas aftermarket sales
grew by 74.5% YoY to INR 601 mn. Replacement market has been
on upward trajectory from Q2FY14 primarily because of
replacement demand for the BS III compliant clutches that were
fitted in CVs in 2010. Exports grew by only 4% but we expect
significant pick up in exports from H2 onwards. We expect OE &
replacement market volumes to grow at a CAGR of 16.7% & 15.4%
respectively between FY14-16E.
EBITDA Margin down 12 bps YoY
Setco reported EBITDA of INR 112 mn, up 47.8% YoY but margins
dipped 12 bps over the same period to 11.8% led by higher material
costs. Material cost increased because of rupee depreciation
(Imports account for ~25% of raw material cost) & increase in
price of certain raw materials including steel. Setco is in talks
with OEMs for price hike & management expects some decision
on pricing front by the end of next month. Employee cost & other
expenses came in at INR 82 mn (8.6% of sales) & INR 180 mn
(18.8% of sales).
Other Highlights
1. Volumes for Clutch Driven Plate & Clutch Cover Assembly grew
by 50.0% & 28.0% YoY respectively.
2. The company plans to incur capex of INR 250 mn in both FY15
& FY16 on normal maintainence & backward integration of
some parts.
August 06, 2014 RESULTUPDATE-Q1FY15
3. Total Debt currently stands at INR 1850 mn & Setco plans to
repay INR 320 mn of debt over the next two years.
4. In order to improve its product quality, Setco, has entered into
a JV with Lingotes Especiales S.A to manufacture high quality
machined ferrous casting products for itself. The company
intends to invest INR 360 mn over the next two years in the JV.
Outlook & Valuation
We expect M&HCV segment to recover & register a CAGR of 16.7%
betweenFY14-16E.GlobalplayerslikeDaimler&Volvohavestarted
manufacturing operations in India with the twin objective of
increasing the domestic presence & making India an export base
for overseas markets. To offer superior quality products at
competitive price, these MNCs would increase insourcing &
localization of auto parts, thereby generating demand for Setco's
clutches. Dependency on M&HCV segment, increased in-sourcing
by MNCs and sizeable market share of ~85% places Setco
Automotive in a sweet spot.
WeexpectSetco'svolumetoregisteraCAGRof16.0%betweenFY14-
16Ewhereasrevenue&PATareexpectedtoclockinaCAGRof19.1%
&132.1%respectivelyoverthesameperiod.EBITDAmarginislikely
to increase by 600 bps to 15.7% between FY14-16E on the back of
pricehikes,lowerdiscounts&benefitsofoperatingleverage.Setco,
being a pure M&HCV auto ancillary, is among the best play of any
recoveryintheCVcycle.WeretainourBUYrecommendationonthe
stock with a target price of INR 159 based on 6.5x FY16E EBITDA.
Shareholding (%) Jun-14
Promoters 63.01
FIIs 21.1
DIIs 0.03
Others 15.86
Relative Price Performance
Key Data
BSE Code 505075
Bloomberg Code SETC IN
Reuters Code SETC.BO
Shares Outstanding (mn) 26.68
Face Value 10
Mcap (INR bn) 3.57
52 Week H/L 141.10/61.95
2W Avg. Vol, BSE 0
Float (INR bn) 1.32
Beta 0.16
(INR mn) FY13 FY14 FY15E FY16E
Net Sales 3994 3899 4508 5532
Growth (%) -7.66 -2.37 15.62 22.70
EBIDTAM (%) 14.18 9.68 12.36 15.69
Adj. PAT 252 106 250 569
Growth (%) 6.30 2.71 5.55 10.29
Adj. EPS (INR) 9.43 3.96 9.37 21.33
P/E(x) 10.60 22.17 14.30 6.28
EV/EBIDTA 7.71 10.96 9.45 5.75
Net Debt/Equity 0.94 0.95 0.82 0.57
RoACE (%) 13.72 10.28 13.48 19.73
RoAE (%) 13.96 5.57 12.19 22.79
Setco Automotive reported Q1FY15 revenue at INR 954 mn which was inline with our estimates but PAT, which came
in at INR 45 mn was below our estimates. EBITDA was up 47.8% at INR 112 mn but margins declined 12 bps YoY
to 11.8%. PAT grew by 9.2% to INR 45 mn due to lower other income (PBT excluding other income was up 4.9x YoY).
We retain our BUY recommendation on the stock with a target price of INR 159 based on 6.5x FY16E EBITDA.
Prashant Biyani
prashant.biyani@spagroupindia.com
Ph. No. 91 33 4011 4800 (Ext. 833)
60
100
140
180
220
Aug-13
Sep-13
Oct-13
Nov-13
Dec-13
Jan-14
Feb-14
Mar-14
Apr-14
May-14
Jun-14
Jul-14
Aug-14
Setco Sensex
2
Auto Ancillaries
Quarterly Financials
Particulars (INR Mn) Q1FY15 Q1FY14 YoY% Q4FY14 QoQ%
Net Sales 954 639 49.37% 1094 -12.76%
Other Income 21 45 -54.63% 73 -71.63%
Total Income 975 684 42.47% 1166 -16.43%
Raw Material Consumed 568 372 52.72% 645 -11.98%
Stock Adjustment 12 -6 NA 56 -78.85%
Employee Expenses 82 65 27.20% 72 14.94%
Other Expenses 180 133 35.70% 225 -20.09%
Total Expenses 842 563 49.58% 998 -15.61%
EBITDA 112 76 47.83% 96 16.88%
Depreciation 30 24 25.74% 30 0.00%
EBIT 82 52 57.85% 66 24.47%
Interest 50 46 8.79% 54 -8.67%
PBT 54 52 2.69% 85 -36.76%
Tax Expense 9 11 -22.02% -3 NA
PAT 45 41 9.22% 88 -48.86%
Extra-ordinary Items 0 0 NA 57 NA
APAT 45 41 9.22% 31 47.06%
Eq Cap (INR Mn) 267 267 0.00% 267 0.00%
FV 10 10 0.00% 10 0.00%
EPS 1.69 1.54 9.22% 1.15 47.06%
EBITDAM (%) 11.76% 11.88% (12 bps) 8.78% 298 bps
OPM (%) 13.92% 18.99% (507 bps) 15.41% (150 bps)
PATM (%) 4.72% 6.45% (173 bps) 2.80% (192 bps)
3
Financials
Income Statement
Year End March (INR mn) FY13 FY14 FY15E FY16E
Net Sales 3994 3899 4508 5532
Growth in Sales (%) -7.66 -2.37 15.62 22.70
Cost of goods sold 2220 2187 2509 3051
Employees Cost 463 522 563 620
Other Expenses 696 766 825 927
Total Expenditure 3427 3522 3951 4664
EBIDTA (without OI) 567 377 557 868
% Growth -21.69 -33.36 47.60 55.74
EBITDA Margin % 14.18 9.68 12.36 15.69
Depreciation/Amortization 123 136 151 165
EBIT 443 242 406 703
EBIT Margin % 11.10 6.20 9.00 12.71
Interest Expense 198 234 234 215
Other Income 49 171 100 130
EBT 295 179 272 619
PAT 252 182 250 569
Exceptionals 0 77 0 0
APAT 252 106 250 569
% Growth -46.14 -58.05 136.80 127.58
APAT Margin % 6.30 2.71 5.55 10.29
Balance Sheet
Year End March (INR mn) FY13 FY14 FY15E FY16E
Sources of funds
Share capital 267 267 267 267
Reserves & Surplus 1537 1628 1785 2230
Total Networth 1803 1895 2052 2497
Total Debt 1726 1850 1750 1550
Total Liabilities 3530 3745 3802 4047
Application of funds
Net Block 1469 1577 1606 1691
Capital Work-in-Progress 40 0 70 70
Investments 368 513 813 873
Total Current Assets 2320 2157 2076 2352
Total Current Liabilities 601 741 752 858
Net Current Assets 1720 1415 1323 1494
Net Deferred Tax Asset (66) (73) (81) (91)
Other Assets 0 312 70 10
Total Assets 3530 3745 3802 4047
Cash Flow
Year End March (INR mn) FY13 FY14 FY15E FY16E
EBT 295 179 272 619
Less: Other Income/Exceptionals (49) (171) (100) (130)
Add:Depreciation 123 136 151 165
Add: Interest paid 198 234 234 215
Direct taxes paid (33) 11 (14) (49)
Change in Working Capital (276) 342 73 (130)
Cash Flow from operations (a) 257 730 616 688
Change in Fixed Assets (563) (244) (180) (250)
Change in CWIP 79 40 (70) 0
Change in Investments (150) (146) (300) (60)
Others 0 (312) 242 61
Cash Flow from Investing (b) (634) (662) (308) (249)
Change in Equity 3 0 0 0
Change in Debt 300 124 (100) (200)
Dividend paid (82) (82) (93) (124)
Interest paid (198) (234) (234) (215)
Others 293 149 124 181
Cash Flow from Financing (c ) 316 (43) (303) (358)
Net Change in Cash (a+b+c) (61) 25 6 81
Opening Cash 88 28 53 58
Closing Cash 28 53 58 139
Key Ratios
Year End March FY13 FY14 FY15E FY16E
Per Share Data (INR)
Reported EPS 9.44 6.83 9.37 21.33
Adj. EPS 9.43 3.96 9.37 21.33
Growth (%) -46.14 -58.05 136.80 127.58
CEPS 14.05 9.05 15.05 27.50
DPS 2.65 2.65 3.00 4.00
BVPS 67.62 71.01 76.90 93.58
Return Ratios (%)
RoACE 13.72 10.28 13.48 19.73
RoANW 13.96 5.57 12.19 22.79
Liquidity Ratios
Net Debt/Equity 0.94 0.95 0.82 0.57
Interest Coverage Ratio 2.25 1.03 1.73 3.28
Current Ratio 3.86 2.91 2.76 2.74
Efficiency Ratios
Asset Turnover Ratio 1.27 1.07 1.19 1.41
Inventory Days 157 190 154 115
Debtor Days 77 70 62 56
Creditor Days 61 67 68 54
Valuation Ratios
P/E(x) 10.60 22.17 14.30 6.28
P/BV (x) 1.48 1.24 1.14 0.94
P/CEPS (x) 7.12 9.69 5.83 3.19
Dividend Yield (%) 2.65 3.02 3.42 4.56
EV/Net Sales (x) 1.09 1.06 1.17 0.90
EV/EBIDTA(x) 7.71 10.96 9.45 5.75
Auto Ancillaries
4
Auto Ancillaries
Disclaimer: This report is for the personal information of the authorized recipient and does not construe to be any investment, legal or taxation advice to you. SPA Securities Limited
(hereinafter referred as SPA) is not soliciting any action based upon it. This report is not for public distribution and has been furnished to you solely for your information and should
not be reproduced or redistributed to any other person in any form. This document is provided for assistance only and is not intended to be and must not alone be taken as the basis
for an investment decision. The intent of this document is not in recommendary nature. The views expressed are those of analyst and the Company may or may not subscribe to
all the views expressed therein The report is based upon information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied upon
such. SPA or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information
contained in this report. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or
consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. SPA or any of its affiliates or employees do not provide,
at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness
for a particular purpose, and non-infringement.
The recipients of this report should rely on their own investigations. SPA and/or its affiliates and/or employees may have interests/ positions, financial or otherwise in the securities mentioned
in this report. SPA has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report.
Disclosure of Interest Statement
1. Analyst ownership of the stock - No
2. Group/Directors ownership of the stock - No
3. Broking relationship with company covered - No
This information is subject to change without any prior notice. SPA reserves the right to make modifications and alternations to this statement as may be required from time to time.
Nevertheless, SPA is committed to providing independent and transparent recommendations to its clients, and would be happy to provide information in response to specific client queries.
SPA Securities Ltd SEBI Reg. Nos.
NSE Cash INB231178238
NSE Future & Option INF231173238
NSE Currency Derivatives INE231178238
BSE Cash INB011178234
BSE Currency Derivatives INE011178234
MCX-SX Cash INB261178231
MCX-SX Future & Option INF261178231
MCX-SX Currency Derivatives INE261178238
USE Currency Derivatives INE271178234
Mutual Fund ARN 77388
OTCEI INB200891838
PMS INP000003179
CDSL DP IN-DP-CDSL-485-2008
NSDL DP IN-DP-NSDL-316-2009
SPACAPITALSERVICES LIMITED
Investment Advisory Services,
AMFI Reg. No. ARN-0007
SPACAPITALADVISORS LIMITED
SEBI registered Category-1
Merchant Bankers
SEBI Regn. No. INM000010825
SPACOMTRADE PRIVATE LIMITED
Member of NCDEX & MCX.
NCDEX TMID-00729,
NCDEX FMC No.NCDEX/TCM/CORP/0714
SPAINSURANCEBROKINGSERVICESLTD
Direct Broker for Life and General
Insurance Broking
IRDA Lic. Code No. DB053/03
For More Information Visit Us At : www.spasecurities.com
Sharad Avasthi Dy Head - Equity Research sharad.avasthi@spagroupindia.com Tel.: +91-33-4011 4800 Ext.832
SPA Securities Ltd: Mittal Court, A-Wing, 10th Floor, Nariman Point, Mumbai - 400 021, Tel. No. : +91-022-4289 5600, Fax: +91 (22) 2657 3708/9

More Related Content

What's hot

Buy Orient Refractories, engineering sector to get boost from infrastructure ...
Buy Orient Refractories, engineering sector to get boost from infrastructure ...Buy Orient Refractories, engineering sector to get boost from infrastructure ...
Buy Orient Refractories, engineering sector to get boost from infrastructure ...IndiaNotes.com
 
Prabhudas lilladher techmahindra_29june_2015
Prabhudas lilladher techmahindra_29june_2015Prabhudas lilladher techmahindra_29june_2015
Prabhudas lilladher techmahindra_29june_2015IndiaNotes.com
 
Domestic / foreign Investment in Pakistan
Domestic / foreign Investment in PakistanDomestic / foreign Investment in Pakistan
Domestic / foreign Investment in PakistanSheikh Hasnain
 
Balkrishna Industries Q4FY14 results better than estimates, buy - Prabhudas L...
Balkrishna Industries Q4FY14 results better than estimates, buy - Prabhudas L...Balkrishna Industries Q4FY14 results better than estimates, buy - Prabhudas L...
Balkrishna Industries Q4FY14 results better than estimates, buy - Prabhudas L...IndiaNotes.com
 
HGSL 1QFY18
HGSL 1QFY18HGSL 1QFY18
HGSL 1QFY18Mohit Jn
 
Public Sector Banks Result Preview 3QFY14E in India Equity Analytics Today | ...
Public Sector Banks Result Preview 3QFY14E in India Equity Analytics Today | ...Public Sector Banks Result Preview 3QFY14E in India Equity Analytics Today | ...
Public Sector Banks Result Preview 3QFY14E in India Equity Analytics Today | ...NARNOLIA SECURITIES LIMITED
 
Apr 2007_SK Trade Call
Apr 2007_SK Trade CallApr 2007_SK Trade Call
Apr 2007_SK Trade CallAlfred Park
 
Spice jet ic- jp morgan-dec'10
Spice jet  ic- jp morgan-dec'10Spice jet  ic- jp morgan-dec'10
Spice jet ic- jp morgan-dec'10Bharat Bhatnagar
 
Bayer india ru4qfy2010-020610
Bayer india ru4qfy2010-020610Bayer india ru4qfy2010-020610
Bayer india ru4qfy2010-020610Angel Broking
 
Special report by epic research of 01 january 2018
Special report by epic research of 01 january  2018Special report by epic research of 01 january  2018
Special report by epic research of 01 january 2018Epic Research
 
04th june, 2012 investment note - bajaj auto ltd
04th june, 2012   investment note - bajaj auto ltd04th june, 2012   investment note - bajaj auto ltd
04th june, 2012 investment note - bajaj auto ltdPushkaraj Jamsandekar
 
Zee 1QFY18
Zee 1QFY18Zee 1QFY18
Zee 1QFY18Mohit Jn
 

What's hot (20)

Equity report 01 june 2015 Ways2Capital
Equity report 01 june 2015 Ways2CapitalEquity report 01 june 2015 Ways2Capital
Equity report 01 june 2015 Ways2Capital
 
Buy Orient Refractories, engineering sector to get boost from infrastructure ...
Buy Orient Refractories, engineering sector to get boost from infrastructure ...Buy Orient Refractories, engineering sector to get boost from infrastructure ...
Buy Orient Refractories, engineering sector to get boost from infrastructure ...
 
Prabhudas lilladher techmahindra_29june_2015
Prabhudas lilladher techmahindra_29june_2015Prabhudas lilladher techmahindra_29june_2015
Prabhudas lilladher techmahindra_29june_2015
 
Domestic / foreign Investment in Pakistan
Domestic / foreign Investment in PakistanDomestic / foreign Investment in Pakistan
Domestic / foreign Investment in Pakistan
 
Daily equity report
Daily equity reportDaily equity report
Daily equity report
 
Equity Research Report Ways2Capital 27 july 2015
Equity Research Report Ways2Capital 27 july 2015 Equity Research Report Ways2Capital 27 july 2015
Equity Research Report Ways2Capital 27 july 2015
 
Balkrishna Industries Q4FY14 results better than estimates, buy - Prabhudas L...
Balkrishna Industries Q4FY14 results better than estimates, buy - Prabhudas L...Balkrishna Industries Q4FY14 results better than estimates, buy - Prabhudas L...
Balkrishna Industries Q4FY14 results better than estimates, buy - Prabhudas L...
 
HGSL 1QFY18
HGSL 1QFY18HGSL 1QFY18
HGSL 1QFY18
 
Public Sector Banks Result Preview 3QFY14E in India Equity Analytics Today | ...
Public Sector Banks Result Preview 3QFY14E in India Equity Analytics Today | ...Public Sector Banks Result Preview 3QFY14E in India Equity Analytics Today | ...
Public Sector Banks Result Preview 3QFY14E in India Equity Analytics Today | ...
 
Apr 2007_SK Trade Call
Apr 2007_SK Trade CallApr 2007_SK Trade Call
Apr 2007_SK Trade Call
 
Daily equity report
Daily equity reportDaily equity report
Daily equity report
 
Ways2Capital equity report 15 june 2015
Ways2Capital equity report 15 june 2015Ways2Capital equity report 15 june 2015
Ways2Capital equity report 15 june 2015
 
Spice jet ic- jp morgan-dec'10
Spice jet  ic- jp morgan-dec'10Spice jet  ic- jp morgan-dec'10
Spice jet ic- jp morgan-dec'10
 
Bayer india ru4qfy2010-020610
Bayer india ru4qfy2010-020610Bayer india ru4qfy2010-020610
Bayer india ru4qfy2010-020610
 
Credit Analysis Of HCC
Credit Analysis Of HCCCredit Analysis Of HCC
Credit Analysis Of HCC
 
Special report by epic research of 01 january 2018
Special report by epic research of 01 january  2018Special report by epic research of 01 january  2018
Special report by epic research of 01 january 2018
 
캐피탈 영문
캐피탈 영문캐피탈 영문
캐피탈 영문
 
Daily equity report
Daily equity reportDaily equity report
Daily equity report
 
04th june, 2012 investment note - bajaj auto ltd
04th june, 2012   investment note - bajaj auto ltd04th june, 2012   investment note - bajaj auto ltd
04th june, 2012 investment note - bajaj auto ltd
 
Zee 1QFY18
Zee 1QFY18Zee 1QFY18
Zee 1QFY18
 

Viewers also liked

Vedanta resources plc.
Vedanta resources plc.Vedanta resources plc.
Vedanta resources plc.Abhay Singh
 
Hindustan Zinc ltd. HydroPlant Internship ppt
Hindustan Zinc ltd. HydroPlant Internship pptHindustan Zinc ltd. HydroPlant Internship ppt
Hindustan Zinc ltd. HydroPlant Internship pptManish Sharma
 
Summer Training report of Hindustan Zinc limited
Summer Training report of Hindustan Zinc limitedSummer Training report of Hindustan Zinc limited
Summer Training report of Hindustan Zinc limitedAkhil Sodani
 

Viewers also liked (9)

Chanderiya Lead Zinc Project
Chanderiya Lead Zinc ProjectChanderiya Lead Zinc Project
Chanderiya Lead Zinc Project
 
HZL
HZLHZL
HZL
 
Vedanta resources plc.
Vedanta resources plc.Vedanta resources plc.
Vedanta resources plc.
 
Vedanta
VedantaVedanta
Vedanta
 
Hindustan Zinc ltd. HydroPlant Internship ppt
Hindustan Zinc ltd. HydroPlant Internship pptHindustan Zinc ltd. HydroPlant Internship ppt
Hindustan Zinc ltd. HydroPlant Internship ppt
 
Summer Training report of Hindustan Zinc limited
Summer Training report of Hindustan Zinc limitedSummer Training report of Hindustan Zinc limited
Summer Training report of Hindustan Zinc limited
 
Zinc ppt
Zinc pptZinc ppt
Zinc ppt
 
Zinc Smelter Project Report
Zinc Smelter Project ReportZinc Smelter Project Report
Zinc Smelter Project Report
 
10 Car Facts
10 Car Facts10 Car Facts
10 Car Facts
 

Similar to Setco Automotive Q1FY15 Results Update - Revenue Inline, PAT Below Estimates

Nirmal pi industries_03_aug15
Nirmal pi industries_03_aug15Nirmal pi industries_03_aug15
Nirmal pi industries_03_aug15IndiaNotes.com
 
Q2FY15: Hold Mahindra & Mahindra Financial Services - Nirmal Bang
Q2FY15: Hold Mahindra & Mahindra Financial Services - Nirmal BangQ2FY15: Hold Mahindra & Mahindra Financial Services - Nirmal Bang
Q2FY15: Hold Mahindra & Mahindra Financial Services - Nirmal BangIndiaNotes.com
 
Multibase India's FY15 net profit up 42% y/y, Firstcall recommend 'Buy'
Multibase India's FY15 net profit up 42% y/y, Firstcall recommend 'Buy'Multibase India's FY15 net profit up 42% y/y, Firstcall recommend 'Buy'
Multibase India's FY15 net profit up 42% y/y, Firstcall recommend 'Buy'IndiaNotes.com
 
PI Industries: Another strong performance; Sales up 16% in Q1FY15
 PI Industries: Another strong performance; Sales up 16% in Q1FY15 PI Industries: Another strong performance; Sales up 16% in Q1FY15
PI Industries: Another strong performance; Sales up 16% in Q1FY15IndiaNotes.com
 
Mahindra &Mahindra Q1FY15 profits better than estimates - Hold - SPA Securities
Mahindra &Mahindra Q1FY15 profits better than estimates - Hold - SPA SecuritiesMahindra &Mahindra Q1FY15 profits better than estimates - Hold - SPA Securities
Mahindra &Mahindra Q1FY15 profits better than estimates - Hold - SPA SecuritiesIndiaNotes.com
 
Bajaj Auto: Margins disappoint as discover woes continue
Bajaj Auto: Margins disappoint as discover woes continueBajaj Auto: Margins disappoint as discover woes continue
Bajaj Auto: Margins disappoint as discover woes continueIndiaNotes.com
 
Mahindra Financial result update: 4QFY15 PAT up 7% YoY and 144% QoQ
Mahindra Financial result update: 4QFY15 PAT up 7% YoY and 144% QoQMahindra Financial result update: 4QFY15 PAT up 7% YoY and 144% QoQ
Mahindra Financial result update: 4QFY15 PAT up 7% YoY and 144% QoQIndiaNotes.com
 
ENIL 1QFY18
ENIL 1QFY18ENIL 1QFY18
ENIL 1QFY18Mohit Jn
 
Lumax Industries quarterly results above estimates; buy
Lumax Industries quarterly results above estimates; buyLumax Industries quarterly results above estimates; buy
Lumax Industries quarterly results above estimates; buyIndiaNotes.com
 
Cipla Q2 disappoints, gearing up for strong H2FY15E
Cipla Q2 disappoints, gearing up for strong H2FY15ECipla Q2 disappoints, gearing up for strong H2FY15E
Cipla Q2 disappoints, gearing up for strong H2FY15EIndiaNotes.com
 
Vaibhav Global Q1FY15: Outlook continues to remain positive; Hold
 Vaibhav Global Q1FY15: Outlook continues to remain positive; Hold Vaibhav Global Q1FY15: Outlook continues to remain positive; Hold
Vaibhav Global Q1FY15: Outlook continues to remain positive; HoldIndiaNotes.com
 
Buy Multibase India, globalisation of the auto component sector to benefit th...
Buy Multibase India, globalisation of the auto component sector to benefit th...Buy Multibase India, globalisation of the auto component sector to benefit th...
Buy Multibase India, globalisation of the auto component sector to benefit th...IndiaNotes.com
 
Intellect 1QFY18
Intellect 1QFY18Intellect 1QFY18
Intellect 1QFY18Mohit Jn
 
Ashok Leyland Q1FY15: Losses narrowed down to Rs48 mn, hold
 Ashok Leyland Q1FY15: Losses narrowed down to Rs48 mn, hold Ashok Leyland Q1FY15: Losses narrowed down to Rs48 mn, hold
Ashok Leyland Q1FY15: Losses narrowed down to Rs48 mn, holdIndiaNotes.com
 
Mastek 1QFY18
Mastek 1QFY18Mastek 1QFY18
Mastek 1QFY18Mohit Jn
 
Zensar Technologies Q1FY15: Results in line with our expectations, buy
 Zensar Technologies Q1FY15: Results in line with our expectations, buy Zensar Technologies Q1FY15: Results in line with our expectations, buy
Zensar Technologies Q1FY15: Results in line with our expectations, buyIndiaNotes.com
 
Q1FY16 Results: Granules India posts good results at profitability level
Q1FY16 Results: Granules India posts good results at profitability levelQ1FY16 Results: Granules India posts good results at profitability level
Q1FY16 Results: Granules India posts good results at profitability levelIndiaNotes.com
 
HSIL Q4FY15: Disappointing growth but margins maintained; Hold
HSIL Q4FY15: Disappointing growth but margins maintained; HoldHSIL Q4FY15: Disappointing growth but margins maintained; Hold
HSIL Q4FY15: Disappointing growth but margins maintained; HoldIndiaNotes.com
 
M M Forgings: Q4FY15 net profit up 42.18% y/y to INR111.15m, Buy
M M Forgings: Q4FY15 net profit up 42.18% y/y to INR111.15m, BuyM M Forgings: Q4FY15 net profit up 42.18% y/y to INR111.15m, Buy
M M Forgings: Q4FY15 net profit up 42.18% y/y to INR111.15m, BuyIndiaNotes.com
 
Q2FY15: Hold Federal Bank for a target of Rs156 - Sushil Finance
Q2FY15: Hold Federal Bank for a target of Rs156 - Sushil FinanceQ2FY15: Hold Federal Bank for a target of Rs156 - Sushil Finance
Q2FY15: Hold Federal Bank for a target of Rs156 - Sushil FinanceIndiaNotes.com
 

Similar to Setco Automotive Q1FY15 Results Update - Revenue Inline, PAT Below Estimates (20)

Nirmal pi industries_03_aug15
Nirmal pi industries_03_aug15Nirmal pi industries_03_aug15
Nirmal pi industries_03_aug15
 
Q2FY15: Hold Mahindra & Mahindra Financial Services - Nirmal Bang
Q2FY15: Hold Mahindra & Mahindra Financial Services - Nirmal BangQ2FY15: Hold Mahindra & Mahindra Financial Services - Nirmal Bang
Q2FY15: Hold Mahindra & Mahindra Financial Services - Nirmal Bang
 
Multibase India's FY15 net profit up 42% y/y, Firstcall recommend 'Buy'
Multibase India's FY15 net profit up 42% y/y, Firstcall recommend 'Buy'Multibase India's FY15 net profit up 42% y/y, Firstcall recommend 'Buy'
Multibase India's FY15 net profit up 42% y/y, Firstcall recommend 'Buy'
 
PI Industries: Another strong performance; Sales up 16% in Q1FY15
 PI Industries: Another strong performance; Sales up 16% in Q1FY15 PI Industries: Another strong performance; Sales up 16% in Q1FY15
PI Industries: Another strong performance; Sales up 16% in Q1FY15
 
Mahindra &Mahindra Q1FY15 profits better than estimates - Hold - SPA Securities
Mahindra &Mahindra Q1FY15 profits better than estimates - Hold - SPA SecuritiesMahindra &Mahindra Q1FY15 profits better than estimates - Hold - SPA Securities
Mahindra &Mahindra Q1FY15 profits better than estimates - Hold - SPA Securities
 
Bajaj Auto: Margins disappoint as discover woes continue
Bajaj Auto: Margins disappoint as discover woes continueBajaj Auto: Margins disappoint as discover woes continue
Bajaj Auto: Margins disappoint as discover woes continue
 
Mahindra Financial result update: 4QFY15 PAT up 7% YoY and 144% QoQ
Mahindra Financial result update: 4QFY15 PAT up 7% YoY and 144% QoQMahindra Financial result update: 4QFY15 PAT up 7% YoY and 144% QoQ
Mahindra Financial result update: 4QFY15 PAT up 7% YoY and 144% QoQ
 
ENIL 1QFY18
ENIL 1QFY18ENIL 1QFY18
ENIL 1QFY18
 
Lumax Industries quarterly results above estimates; buy
Lumax Industries quarterly results above estimates; buyLumax Industries quarterly results above estimates; buy
Lumax Industries quarterly results above estimates; buy
 
Cipla Q2 disappoints, gearing up for strong H2FY15E
Cipla Q2 disappoints, gearing up for strong H2FY15ECipla Q2 disappoints, gearing up for strong H2FY15E
Cipla Q2 disappoints, gearing up for strong H2FY15E
 
Vaibhav Global Q1FY15: Outlook continues to remain positive; Hold
 Vaibhav Global Q1FY15: Outlook continues to remain positive; Hold Vaibhav Global Q1FY15: Outlook continues to remain positive; Hold
Vaibhav Global Q1FY15: Outlook continues to remain positive; Hold
 
Buy Multibase India, globalisation of the auto component sector to benefit th...
Buy Multibase India, globalisation of the auto component sector to benefit th...Buy Multibase India, globalisation of the auto component sector to benefit th...
Buy Multibase India, globalisation of the auto component sector to benefit th...
 
Intellect 1QFY18
Intellect 1QFY18Intellect 1QFY18
Intellect 1QFY18
 
Ashok Leyland Q1FY15: Losses narrowed down to Rs48 mn, hold
 Ashok Leyland Q1FY15: Losses narrowed down to Rs48 mn, hold Ashok Leyland Q1FY15: Losses narrowed down to Rs48 mn, hold
Ashok Leyland Q1FY15: Losses narrowed down to Rs48 mn, hold
 
Mastek 1QFY18
Mastek 1QFY18Mastek 1QFY18
Mastek 1QFY18
 
Zensar Technologies Q1FY15: Results in line with our expectations, buy
 Zensar Technologies Q1FY15: Results in line with our expectations, buy Zensar Technologies Q1FY15: Results in line with our expectations, buy
Zensar Technologies Q1FY15: Results in line with our expectations, buy
 
Q1FY16 Results: Granules India posts good results at profitability level
Q1FY16 Results: Granules India posts good results at profitability levelQ1FY16 Results: Granules India posts good results at profitability level
Q1FY16 Results: Granules India posts good results at profitability level
 
HSIL Q4FY15: Disappointing growth but margins maintained; Hold
HSIL Q4FY15: Disappointing growth but margins maintained; HoldHSIL Q4FY15: Disappointing growth but margins maintained; Hold
HSIL Q4FY15: Disappointing growth but margins maintained; Hold
 
M M Forgings: Q4FY15 net profit up 42.18% y/y to INR111.15m, Buy
M M Forgings: Q4FY15 net profit up 42.18% y/y to INR111.15m, BuyM M Forgings: Q4FY15 net profit up 42.18% y/y to INR111.15m, Buy
M M Forgings: Q4FY15 net profit up 42.18% y/y to INR111.15m, Buy
 
Q2FY15: Hold Federal Bank for a target of Rs156 - Sushil Finance
Q2FY15: Hold Federal Bank for a target of Rs156 - Sushil FinanceQ2FY15: Hold Federal Bank for a target of Rs156 - Sushil Finance
Q2FY15: Hold Federal Bank for a target of Rs156 - Sushil Finance
 

More from IndiaNotes.com

Fce glaxo smithkline_12aug15
Fce glaxo smithkline_12aug15Fce glaxo smithkline_12aug15
Fce glaxo smithkline_12aug15IndiaNotes.com
 
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaGSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaIndiaNotes.com
 
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaGSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaIndiaNotes.com
 
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccines
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccinesHester Biosciences gets manufacturing licence for 2 additional poultry vaccines
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccinesIndiaNotes.com
 
Vidhi Dyestuffs: To keep its growth story in the coming quarters also
Vidhi Dyestuffs: To keep its growth story in the coming quarters alsoVidhi Dyestuffs: To keep its growth story in the coming quarters also
Vidhi Dyestuffs: To keep its growth story in the coming quarters alsoIndiaNotes.com
 
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacity
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacityApollo Tyres approves further expansion of the Truck & Bus radial tyre capacity
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacityIndiaNotes.com
 
Grasim Industries reports improved performance in Q1FY16
Grasim Industries reports improved performance in Q1FY16Grasim Industries reports improved performance in Q1FY16
Grasim Industries reports improved performance in Q1FY16IndiaNotes.com
 
Cummins India: No interest burden being free from long-term or short-term debt
Cummins India: No interest burden being free from long-term or short-term debtCummins India: No interest burden being free from long-term or short-term debt
Cummins India: No interest burden being free from long-term or short-term debtIndiaNotes.com
 
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...IndiaNotes.com
 
Capital First: Long-term credit rating is rated highly at AA+ by CARE
Capital First: Long-term credit rating is rated highly at AA+ by CARECapital First: Long-term credit rating is rated highly at AA+ by CARE
Capital First: Long-term credit rating is rated highly at AA+ by CAREIndiaNotes.com
 
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...IndiaNotes.com
 
Canara Bank's operating performance to improve in remaining 9MFY16E
Canara Bank's operating performance to improve in remaining 9MFY16ECanara Bank's operating performance to improve in remaining 9MFY16E
Canara Bank's operating performance to improve in remaining 9MFY16EIndiaNotes.com
 
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...IndiaNotes.com
 
Hexaware Technologies adds 9 clients in Q2CY15, Buy
Hexaware Technologies adds 9 clients in Q2CY15, BuyHexaware Technologies adds 9 clients in Q2CY15, Buy
Hexaware Technologies adds 9 clients in Q2CY15, BuyIndiaNotes.com
 
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; BuyPI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; BuyIndiaNotes.com
 
Torrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price target
Torrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price targetTorrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price target
Torrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price targetIndiaNotes.com
 
IndiaNivesh maintain 'buy' on this textile scrip with upgraded target after Q...
IndiaNivesh maintain 'buy' on this textile scrip with upgraded target after Q...IndiaNivesh maintain 'buy' on this textile scrip with upgraded target after Q...
IndiaNivesh maintain 'buy' on this textile scrip with upgraded target after Q...IndiaNotes.com
 
Agro Tech Foods: Demonstrates continued strong growth in tough environment; Buy
Agro Tech Foods: Demonstrates continued strong growth in tough environment; BuyAgro Tech Foods: Demonstrates continued strong growth in tough environment; Buy
Agro Tech Foods: Demonstrates continued strong growth in tough environment; BuyIndiaNotes.com
 

More from IndiaNotes.com (20)

Fce glaxo smithkline_12aug15
Fce glaxo smithkline_12aug15Fce glaxo smithkline_12aug15
Fce glaxo smithkline_12aug15
 
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaGSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
 
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaGSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
 
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccines
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccinesHester Biosciences gets manufacturing licence for 2 additional poultry vaccines
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccines
 
Vidhi Dyestuffs: To keep its growth story in the coming quarters also
Vidhi Dyestuffs: To keep its growth story in the coming quarters alsoVidhi Dyestuffs: To keep its growth story in the coming quarters also
Vidhi Dyestuffs: To keep its growth story in the coming quarters also
 
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacity
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacityApollo Tyres approves further expansion of the Truck & Bus radial tyre capacity
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacity
 
Grasim Industries reports improved performance in Q1FY16
Grasim Industries reports improved performance in Q1FY16Grasim Industries reports improved performance in Q1FY16
Grasim Industries reports improved performance in Q1FY16
 
Cummins India: No interest burden being free from long-term or short-term debt
Cummins India: No interest burden being free from long-term or short-term debtCummins India: No interest burden being free from long-term or short-term debt
Cummins India: No interest burden being free from long-term or short-term debt
 
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
 
Capital First: Long-term credit rating is rated highly at AA+ by CARE
Capital First: Long-term credit rating is rated highly at AA+ by CARECapital First: Long-term credit rating is rated highly at AA+ by CARE
Capital First: Long-term credit rating is rated highly at AA+ by CARE
 
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
 
Canara Bank's operating performance to improve in remaining 9MFY16E
Canara Bank's operating performance to improve in remaining 9MFY16ECanara Bank's operating performance to improve in remaining 9MFY16E
Canara Bank's operating performance to improve in remaining 9MFY16E
 
Nirmal lupin 06_aug15
Nirmal lupin 06_aug15Nirmal lupin 06_aug15
Nirmal lupin 06_aug15
 
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
 
Hexaware Technologies adds 9 clients in Q2CY15, Buy
Hexaware Technologies adds 9 clients in Q2CY15, BuyHexaware Technologies adds 9 clients in Q2CY15, Buy
Hexaware Technologies adds 9 clients in Q2CY15, Buy
 
Fce thermax 31_jul15
Fce thermax 31_jul15Fce thermax 31_jul15
Fce thermax 31_jul15
 
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; BuyPI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
 
Torrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price target
Torrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price targetTorrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price target
Torrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price target
 
IndiaNivesh maintain 'buy' on this textile scrip with upgraded target after Q...
IndiaNivesh maintain 'buy' on this textile scrip with upgraded target after Q...IndiaNivesh maintain 'buy' on this textile scrip with upgraded target after Q...
IndiaNivesh maintain 'buy' on this textile scrip with upgraded target after Q...
 
Agro Tech Foods: Demonstrates continued strong growth in tough environment; Buy
Agro Tech Foods: Demonstrates continued strong growth in tough environment; BuyAgro Tech Foods: Demonstrates continued strong growth in tough environment; Buy
Agro Tech Foods: Demonstrates continued strong growth in tough environment; Buy
 

Setco Automotive Q1FY15 Results Update - Revenue Inline, PAT Below Estimates

  • 1. 1 Setco Automotive Sensex: 25908 CMP:INR134 Target: INR 159 Auto Ancillaries OE sales up 23.2%, replacement sales up 74.5% OE sales grew 23.2% YoY to INR 301 mn whereas aftermarket sales grew by 74.5% YoY to INR 601 mn. Replacement market has been on upward trajectory from Q2FY14 primarily because of replacement demand for the BS III compliant clutches that were fitted in CVs in 2010. Exports grew by only 4% but we expect significant pick up in exports from H2 onwards. We expect OE & replacement market volumes to grow at a CAGR of 16.7% & 15.4% respectively between FY14-16E. EBITDA Margin down 12 bps YoY Setco reported EBITDA of INR 112 mn, up 47.8% YoY but margins dipped 12 bps over the same period to 11.8% led by higher material costs. Material cost increased because of rupee depreciation (Imports account for ~25% of raw material cost) & increase in price of certain raw materials including steel. Setco is in talks with OEMs for price hike & management expects some decision on pricing front by the end of next month. Employee cost & other expenses came in at INR 82 mn (8.6% of sales) & INR 180 mn (18.8% of sales). Other Highlights 1. Volumes for Clutch Driven Plate & Clutch Cover Assembly grew by 50.0% & 28.0% YoY respectively. 2. The company plans to incur capex of INR 250 mn in both FY15 & FY16 on normal maintainence & backward integration of some parts. August 06, 2014 RESULTUPDATE-Q1FY15 3. Total Debt currently stands at INR 1850 mn & Setco plans to repay INR 320 mn of debt over the next two years. 4. In order to improve its product quality, Setco, has entered into a JV with Lingotes Especiales S.A to manufacture high quality machined ferrous casting products for itself. The company intends to invest INR 360 mn over the next two years in the JV. Outlook & Valuation We expect M&HCV segment to recover & register a CAGR of 16.7% betweenFY14-16E.GlobalplayerslikeDaimler&Volvohavestarted manufacturing operations in India with the twin objective of increasing the domestic presence & making India an export base for overseas markets. To offer superior quality products at competitive price, these MNCs would increase insourcing & localization of auto parts, thereby generating demand for Setco's clutches. Dependency on M&HCV segment, increased in-sourcing by MNCs and sizeable market share of ~85% places Setco Automotive in a sweet spot. WeexpectSetco'svolumetoregisteraCAGRof16.0%betweenFY14- 16Ewhereasrevenue&PATareexpectedtoclockinaCAGRof19.1% &132.1%respectivelyoverthesameperiod.EBITDAmarginislikely to increase by 600 bps to 15.7% between FY14-16E on the back of pricehikes,lowerdiscounts&benefitsofoperatingleverage.Setco, being a pure M&HCV auto ancillary, is among the best play of any recoveryintheCVcycle.WeretainourBUYrecommendationonthe stock with a target price of INR 159 based on 6.5x FY16E EBITDA. Shareholding (%) Jun-14 Promoters 63.01 FIIs 21.1 DIIs 0.03 Others 15.86 Relative Price Performance Key Data BSE Code 505075 Bloomberg Code SETC IN Reuters Code SETC.BO Shares Outstanding (mn) 26.68 Face Value 10 Mcap (INR bn) 3.57 52 Week H/L 141.10/61.95 2W Avg. Vol, BSE 0 Float (INR bn) 1.32 Beta 0.16 (INR mn) FY13 FY14 FY15E FY16E Net Sales 3994 3899 4508 5532 Growth (%) -7.66 -2.37 15.62 22.70 EBIDTAM (%) 14.18 9.68 12.36 15.69 Adj. PAT 252 106 250 569 Growth (%) 6.30 2.71 5.55 10.29 Adj. EPS (INR) 9.43 3.96 9.37 21.33 P/E(x) 10.60 22.17 14.30 6.28 EV/EBIDTA 7.71 10.96 9.45 5.75 Net Debt/Equity 0.94 0.95 0.82 0.57 RoACE (%) 13.72 10.28 13.48 19.73 RoAE (%) 13.96 5.57 12.19 22.79 Setco Automotive reported Q1FY15 revenue at INR 954 mn which was inline with our estimates but PAT, which came in at INR 45 mn was below our estimates. EBITDA was up 47.8% at INR 112 mn but margins declined 12 bps YoY to 11.8%. PAT grew by 9.2% to INR 45 mn due to lower other income (PBT excluding other income was up 4.9x YoY). We retain our BUY recommendation on the stock with a target price of INR 159 based on 6.5x FY16E EBITDA. Prashant Biyani prashant.biyani@spagroupindia.com Ph. No. 91 33 4011 4800 (Ext. 833) 60 100 140 180 220 Aug-13 Sep-13 Oct-13 Nov-13 Dec-13 Jan-14 Feb-14 Mar-14 Apr-14 May-14 Jun-14 Jul-14 Aug-14 Setco Sensex
  • 2. 2 Auto Ancillaries Quarterly Financials Particulars (INR Mn) Q1FY15 Q1FY14 YoY% Q4FY14 QoQ% Net Sales 954 639 49.37% 1094 -12.76% Other Income 21 45 -54.63% 73 -71.63% Total Income 975 684 42.47% 1166 -16.43% Raw Material Consumed 568 372 52.72% 645 -11.98% Stock Adjustment 12 -6 NA 56 -78.85% Employee Expenses 82 65 27.20% 72 14.94% Other Expenses 180 133 35.70% 225 -20.09% Total Expenses 842 563 49.58% 998 -15.61% EBITDA 112 76 47.83% 96 16.88% Depreciation 30 24 25.74% 30 0.00% EBIT 82 52 57.85% 66 24.47% Interest 50 46 8.79% 54 -8.67% PBT 54 52 2.69% 85 -36.76% Tax Expense 9 11 -22.02% -3 NA PAT 45 41 9.22% 88 -48.86% Extra-ordinary Items 0 0 NA 57 NA APAT 45 41 9.22% 31 47.06% Eq Cap (INR Mn) 267 267 0.00% 267 0.00% FV 10 10 0.00% 10 0.00% EPS 1.69 1.54 9.22% 1.15 47.06% EBITDAM (%) 11.76% 11.88% (12 bps) 8.78% 298 bps OPM (%) 13.92% 18.99% (507 bps) 15.41% (150 bps) PATM (%) 4.72% 6.45% (173 bps) 2.80% (192 bps)
  • 3. 3 Financials Income Statement Year End March (INR mn) FY13 FY14 FY15E FY16E Net Sales 3994 3899 4508 5532 Growth in Sales (%) -7.66 -2.37 15.62 22.70 Cost of goods sold 2220 2187 2509 3051 Employees Cost 463 522 563 620 Other Expenses 696 766 825 927 Total Expenditure 3427 3522 3951 4664 EBIDTA (without OI) 567 377 557 868 % Growth -21.69 -33.36 47.60 55.74 EBITDA Margin % 14.18 9.68 12.36 15.69 Depreciation/Amortization 123 136 151 165 EBIT 443 242 406 703 EBIT Margin % 11.10 6.20 9.00 12.71 Interest Expense 198 234 234 215 Other Income 49 171 100 130 EBT 295 179 272 619 PAT 252 182 250 569 Exceptionals 0 77 0 0 APAT 252 106 250 569 % Growth -46.14 -58.05 136.80 127.58 APAT Margin % 6.30 2.71 5.55 10.29 Balance Sheet Year End March (INR mn) FY13 FY14 FY15E FY16E Sources of funds Share capital 267 267 267 267 Reserves & Surplus 1537 1628 1785 2230 Total Networth 1803 1895 2052 2497 Total Debt 1726 1850 1750 1550 Total Liabilities 3530 3745 3802 4047 Application of funds Net Block 1469 1577 1606 1691 Capital Work-in-Progress 40 0 70 70 Investments 368 513 813 873 Total Current Assets 2320 2157 2076 2352 Total Current Liabilities 601 741 752 858 Net Current Assets 1720 1415 1323 1494 Net Deferred Tax Asset (66) (73) (81) (91) Other Assets 0 312 70 10 Total Assets 3530 3745 3802 4047 Cash Flow Year End March (INR mn) FY13 FY14 FY15E FY16E EBT 295 179 272 619 Less: Other Income/Exceptionals (49) (171) (100) (130) Add:Depreciation 123 136 151 165 Add: Interest paid 198 234 234 215 Direct taxes paid (33) 11 (14) (49) Change in Working Capital (276) 342 73 (130) Cash Flow from operations (a) 257 730 616 688 Change in Fixed Assets (563) (244) (180) (250) Change in CWIP 79 40 (70) 0 Change in Investments (150) (146) (300) (60) Others 0 (312) 242 61 Cash Flow from Investing (b) (634) (662) (308) (249) Change in Equity 3 0 0 0 Change in Debt 300 124 (100) (200) Dividend paid (82) (82) (93) (124) Interest paid (198) (234) (234) (215) Others 293 149 124 181 Cash Flow from Financing (c ) 316 (43) (303) (358) Net Change in Cash (a+b+c) (61) 25 6 81 Opening Cash 88 28 53 58 Closing Cash 28 53 58 139 Key Ratios Year End March FY13 FY14 FY15E FY16E Per Share Data (INR) Reported EPS 9.44 6.83 9.37 21.33 Adj. EPS 9.43 3.96 9.37 21.33 Growth (%) -46.14 -58.05 136.80 127.58 CEPS 14.05 9.05 15.05 27.50 DPS 2.65 2.65 3.00 4.00 BVPS 67.62 71.01 76.90 93.58 Return Ratios (%) RoACE 13.72 10.28 13.48 19.73 RoANW 13.96 5.57 12.19 22.79 Liquidity Ratios Net Debt/Equity 0.94 0.95 0.82 0.57 Interest Coverage Ratio 2.25 1.03 1.73 3.28 Current Ratio 3.86 2.91 2.76 2.74 Efficiency Ratios Asset Turnover Ratio 1.27 1.07 1.19 1.41 Inventory Days 157 190 154 115 Debtor Days 77 70 62 56 Creditor Days 61 67 68 54 Valuation Ratios P/E(x) 10.60 22.17 14.30 6.28 P/BV (x) 1.48 1.24 1.14 0.94 P/CEPS (x) 7.12 9.69 5.83 3.19 Dividend Yield (%) 2.65 3.02 3.42 4.56 EV/Net Sales (x) 1.09 1.06 1.17 0.90 EV/EBIDTA(x) 7.71 10.96 9.45 5.75 Auto Ancillaries
  • 4. 4 Auto Ancillaries Disclaimer: This report is for the personal information of the authorized recipient and does not construe to be any investment, legal or taxation advice to you. SPA Securities Limited (hereinafter referred as SPA) is not soliciting any action based upon it. This report is not for public distribution and has been furnished to you solely for your information and should not be reproduced or redistributed to any other person in any form. This document is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The intent of this document is not in recommendary nature. The views expressed are those of analyst and the Company may or may not subscribe to all the views expressed therein The report is based upon information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied upon such. SPA or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. SPA or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations. SPA and/or its affiliates and/or employees may have interests/ positions, financial or otherwise in the securities mentioned in this report. SPA has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report. Disclosure of Interest Statement 1. Analyst ownership of the stock - No 2. Group/Directors ownership of the stock - No 3. Broking relationship with company covered - No This information is subject to change without any prior notice. SPA reserves the right to make modifications and alternations to this statement as may be required from time to time. Nevertheless, SPA is committed to providing independent and transparent recommendations to its clients, and would be happy to provide information in response to specific client queries. SPA Securities Ltd SEBI Reg. Nos. NSE Cash INB231178238 NSE Future & Option INF231173238 NSE Currency Derivatives INE231178238 BSE Cash INB011178234 BSE Currency Derivatives INE011178234 MCX-SX Cash INB261178231 MCX-SX Future & Option INF261178231 MCX-SX Currency Derivatives INE261178238 USE Currency Derivatives INE271178234 Mutual Fund ARN 77388 OTCEI INB200891838 PMS INP000003179 CDSL DP IN-DP-CDSL-485-2008 NSDL DP IN-DP-NSDL-316-2009 SPACAPITALSERVICES LIMITED Investment Advisory Services, AMFI Reg. No. ARN-0007 SPACAPITALADVISORS LIMITED SEBI registered Category-1 Merchant Bankers SEBI Regn. No. INM000010825 SPACOMTRADE PRIVATE LIMITED Member of NCDEX & MCX. NCDEX TMID-00729, NCDEX FMC No.NCDEX/TCM/CORP/0714 SPAINSURANCEBROKINGSERVICESLTD Direct Broker for Life and General Insurance Broking IRDA Lic. Code No. DB053/03 For More Information Visit Us At : www.spasecurities.com Sharad Avasthi Dy Head - Equity Research sharad.avasthi@spagroupindia.com Tel.: +91-33-4011 4800 Ext.832 SPA Securities Ltd: Mittal Court, A-Wing, 10th Floor, Nariman Point, Mumbai - 400 021, Tel. No. : +91-022-4289 5600, Fax: +91 (22) 2657 3708/9